Total item
Cart Subtotal
$0.00 - Hirosumi Tamura, .et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
Biological Activity
PHA-793887, a novel potent inhibitor of Cdk, target on kinds of cyclin-dependent kinase under low concentrations and poses high activity against several cancer cell lines.
Targets
| Target | Value |
|---|---|
| CDK5/p25 | IC50: 5nM |
| CDK2/CyclinA | IC50: 8nM |
| CDK2/CyclinE | IC50: 8nM |
| CDK7/CyclinH | IC50: 10nM |
| CDK1/CyclinB | IC50: 60nM |
| CDK4/CyclinD1 | IC50: 62nM |
| GSK-3β | IC50: 79nM |
| CDK9/CyclinT1 | IC50: 138nM |
| In vitro (25°C) | DMSO | 61 mg/mL (168.75 mM) | |
| Water | Insoluble | ||
| Ethanol | 61 mg/mL (168.75 mM) | ||
| In vivo | 30% propylene glycol, 5% Tween 80, 65% D5W | 14 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 27.66 mL | 138.31 mL | 276.63 mL |
| 0.5 mM | 5.53 mL | 27.66 mL | 55.33 mL |
| 1 mM | 2.77 mL | 13.83 mL | 27.66 mL |
| 5 mM | 0.55 mL | 2.77 mL | 5.53 mL |
*The above data is based on the productmolecular weight 361.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A10716 |
|---|---|
| Actions | Inhibitor |
| CAS No. | 718630-59-2 |
| Formula | C19H31N5O2 |
| M. Wt | 361.5 |
| Purity | >98% |
| Synonyms | PHA793887 |
| SMILES | CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
PD 0332991 HCl (Palbociclib)
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activit…
AT7519 HCl
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhib…
NVP-LCQ195
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
Flavopiridol HCl
Flavopiridol HCl is an inhibitor of cyclin-dependent kinases. The (-)-cis form induces apoptosis in particular tumor cells.
P276-00
P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. In Phase 2/3
Dinaciclib (SCH 727965)
Dinaciclib (SCH 727965) is a potent and selective cyclin-dependent kinase (CDK) inhibitor, selectively inhibiting CDK1, CDK2, CDK5 and CDK9 …
CVT-313
CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 2…
AT7519
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhib…
Keywords:buy PHA-793887 | PHA-793887 Supplier | purchase | cost | manufacturer | order | distributor | buy 718630-59-2| 718630-59-2 Supplier | purchase 718630-59-2 | 718630-59-2 cost | 718630-59-2 manufacturer | order 718630-59-2 | 718630-59-2 distributor
Adooq Quality Guarantee
We promise all products perform as described.